Vyne Therapeutics INC Form 4 insider transactions

Tyler Zeronda, CFO of VYNE Therapeutics, reports the disposal of 92 common stock shares to cover tax obligations related to vesting restricted stock units on July 1, 2024.

Iain Stuart, Chief Scientific Officer of VYNE Therapeutics, reports a transaction involving the withholding of shares to cover tax obligations related to vesting restricted stock units.

Mutya Harsch, Chief Legal Officer and GC of VYNE Therapeutics, sold shares to cover tax withholding requirements related to vesting restricted stock units.

David Domzalski, CEO of VYNE Therapeutics, reports disposition of shares to cover tax obligations related to vesting of restricted stock units.

David Domzalski, CEO of VYNE Therapeutics, acquired 4,429 shares of common stock through the company's Employee Share Purchase Plan (ESPP) at a price of $2.159 per share.

Tyler Zeronda, CFO of VYNE Therapeutics Inc., reports disposing of 94 shares of common stock on April 1, 2024, to cover tax withholding requirements related to vesting restricted stock units.

Chief Scientific Officer Iain Stuart reports a transaction involving Vyne Therapeutics Inc. common stock due to tax withholding requirements.

Mutya Harsch, Chief Legal Officer and GC of VYNE Therapeutics, disposed of 161 shares to cover tax withholding requirements related to vesting restricted stock units.

David Domzalski, CEO of VYNE Therapeutics, reports the disposal of 1,004 common stock shares to cover tax obligations related to vesting restricted stock units on April 1, 2024.